At the 2013 Leipzig Interventional Course meeting in Leipzig, Germany, 30-day results from the ESPRIT I trial were presented. The trial evaluated performance of the Esprit drug-eluting bioresorbable vascular scaffold (BVS) by Abbott in subjects with symptomatic atherosclerotic disease of the SFA or iliac arteries. At the end of 30 days, no clinical endpoint events or scaffold thrombosis was observed.
Vascular Disease Management interviewed Johannes Lammer, MD, professor of radiology at the Medical University of Vienna, Austria, and principal investigator for the ESPRIT I trial about the 30-day results. We asked Dr. Lammer what was most remarkable about the results, and he described the mechanical properties of the Esprit BVS.
“The poly-L-lactide scaffold is placed by balloon expansion and acts like a self-expandable stent thereafter. The average in-segment stenosis of 80% (including total occlusions in 23%) was reduced to 13% after the procedure. Before treatment, 91.4% had severe-moderate claudication (Rutherford-Becker clinical category 2-3), after treatment 97.0% had no claudication or mild claudication (Rutherford-Becker clinical category 0-1) with an Ankle Brachial Index of 1.0,” said Dr. Lammer.